Fitness + RecoveryClinical / investigationalEarly humanUpdated 2026-04-24

Peptide reference file

AOD-9604

Trending #6 in Fitness21.8k searches/moMixed

AOD-9604 is a growth-hormone fragment analog discussed for body-composition effects without the full endocrine profile of GH itself.

Current readout: early human evidence, clinical / investigational status, investigational approval state, human evidence appears in the current trail, registered trials are linked, and 4 linked sources in the seed trail.

PubChem CID 71300630 | 18 PubMed results | 0 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

AOD-9604 is mostly discussed because it stays popular because it sounds like a fat-loss peptide with less hormonal baggage than classic GH-axis compounds.

The public claim is straightforward: It stays popular because it sounds like a fat-loss peptide with less hormonal baggage than classic GH-axis compounds. More studied than many research peptides, but still not an approved mainstream fat-loss medicine.

In plain language, aOD-9604 is a growth-hormone fragment analog discussed for body-composition effects without the full endocrine profile of GH itself.

Early humanClinical / investigational
GH fragmentLipolysis discussionBody composition

Aliases: Anti-obesity drug 9604, HGH fragment 176-191

SpecimenAOD-9604 specimen
CCCCHHHHHHHNOS
Formula
C78H123N23O23S2
Mass
1815.1
Evidence
Early human
Elements
5

Most commonly discussed in relation to GH fragment, Lipolysis discussion, Body composition.

What AOD-9604 is

AOD-9604 is a growth-hormone fragment analog discussed for body-composition effects without the full endocrine profile of GH itself.

AOD-9604 is grouped under Fitness + Recovery / Fat Loss + GLP-1s on PeptideFactCheck because it stays popular because it sounds like a fat-loss peptide with less hormonal baggage than classic GH-axis compounds.

The useful starting point is to separate the molecule itself from the internet story around it. It stays popular because it sounds like a fat-loss peptide with less hormonal baggage than classic GH-axis compounds.

Why people keep looking it up

It stays popular because it sounds like a fat-loss peptide with less hormonal baggage than classic GH-axis compounds.

AOD-9604 is a growth-hormone fragment analog discussed for body-composition effects without the full endocrine profile of GH itself.

AOD-9604 tends to stay in the conversation because it touches a familiar public theme: gh fragment, lipolysis discussion, and body composition. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

More studied than many research peptides, but still not an approved mainstream fat-loss medicine.

Some human investigation exists, but the broad internet fat-loss story still needs more careful interpretation.

Preclinical work and fragment-based rationale drive much of the remaining interest.

Why this page carries the current tier: More studied than many research peptides, but still not an approved mainstream fat-loss medicine.

The current seed trail for AOD-9604 is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.

Safety, limits, and regulatory context

The gap between fragment pharmacology and actual durable fat-loss benefit remains important.

No current FDA-approved AOD-9604 product is represented in this seed set.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for AOD-9604. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for AOD-9604 is CID 71300630. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
71300630
Formula
C78H123N23O23S2
Molecular weight
1815.1
InChIKey
GVIYUKXRXPXMQM-BPXGDYAESA-N

Matched synonyms include AOD 9604, AOD9604, AOD-9604, RefChem:113278, Tyr-somatostatin (177-191), Somatostatin (177-191), Tyr-, Somatostatin (177-191), tyrosyl-, 221231-10-3.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for AOD-9604 returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.

Literature snapshot

The current PubMed query for AOD-9604 returns 18 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.